KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-Current Debt (2022 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Non-Current Debt for 4 consecutive years, with $126.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 4.42% to $126.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $126.6 million through Dec 2025, down 4.42% year-over-year, with the annual reading at $126.6 million for FY2025, 4.42% down from the prior year.
  • Non-Current Debt hit $126.6 million in Q4 2025 for Adaptive Biotechnologies, down from $129.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $132.7 million in Q3 2024 to a low of $125.4 million in Q4 2022.
  • Historically, Non-Current Debt has averaged $130.0 million across 4 years, with a median of $130.7 million in 2023.
  • Biggest five-year swings in Non-Current Debt: increased 4.71% in 2024 and later fell 4.42% in 2025.
  • Year by year, Non-Current Debt stood at $125.4 million in 2022, then increased by 4.23% to $130.7 million in 2023, then increased by 1.34% to $132.4 million in 2024, then decreased by 4.42% to $126.6 million in 2025.
  • Business Quant data shows Non-Current Debt for ADPT at $126.6 million in Q4 2025, $129.4 million in Q3 2025, and $130.5 million in Q2 2025.